Why Is STTK Stock Up 130% Today?
$Shattuck Labs (STTK.US)$ stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial.
These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m acute myeloid leukemia (AML) patients. Specifically, this focuses on initial data from a dose expansion announced earlier this year.
These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m acute myeloid leukemia (AML) patients. Specifically, this focuses on initial data from a dose expansion announced earlier this year.
If the company continues to see positive results from this clinical trial, more studies will likely follow. Investors are hoping for these as it puts Shattuck Labs closer to commercializing SL-172154. If that happens, it could bring a new source of revenue to the company.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
